oxazoles has been researched along with Insulin Sensitivity in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (15.63) | 18.2507 |
| 2000's | 12 (37.50) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, D; Guo, F; Holm, L; Li, Y; Liu, HY; Zhang, K; Zhou, B | 1 |
| Buse, JB; Grobbee, DE; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Chen, W; Li, S; Meng, A; Wang, L; Xie, X; Zhang, N; Zhou, X | 1 |
| Cha, DR; Cha, JJ; Han, JY; Hyun, YY; Kang, YS; Kim, HW; Kim, JE; Lee, JE; Lee, MH; Nam, DH; Song, HK | 1 |
| Cersosimo, E; Coletta, DK; DeFronzo, RA; Fernandez, M; Gastaldelli, A; Musi, N | 1 |
| Andjelkovic, M; Buse, JB; Durrwell, L; El Azzouzi, B; Henry, RR; Herz, M; Jaekel, K; Mingrino, R; Wu, H | 1 |
| Andjelkovic, M; Fischer, A; Gastaldelli, A; Heise, T; Herz, M; Nosek, L; Stirban, AO | 1 |
| Calabriso, N; Carluccio, MA; De Caterina, R; Massaro, M; Pellegrino, M; Scoditti, E; Storelli, C; Wabitsch, M; Wright, M | 1 |
| Cho, B; Choe, SS; Choi, EB; Choi, SH; Chung, H; Chung, YS; Jeong, HW; Kim, HR; Kim, JB; Kim, WS; Lee, GY; Lee, HK; Lee, JH; Lee, JW; Park, SB; Ro, S; Shin, D; Shin, HJ; Yon, GH | 1 |
| Lecka-Czernik, B | 1 |
| Bénardeau, A; Hansen, BC; Meyer, M; Mizrahi, J; Sebokova, E; Tigno, XT | 1 |
| Choe, SS; Choi, EB; Chung, H; Jeong, HW; Kim, HS; Kim, JB; Kim, KH; Kim, WS; Lee, GY; Lee, H; Lee, HK; Lee, JH; Lee, JW; Park, HS; Park, KS; Park, SB; Ro, S; Shin, D; Shin, HJ | 1 |
| Casolaro, A; Cersosimo, E; DeFronzo, RA; Fernandez, M; Ferrannini, E; Gastaldelli, A; Hardies, J; Musi, N; Petz, R; Tantiwong, P; Triplitt, C | 1 |
| Cano, C; Decara, JM; Fresno, N; Macias-González, M; Pavón, FJ; Pérez-Fernández, R; Rivera, P; Rodríguez de Fonseca, F; Romero-Cuevas, M; Serrano, A; Suárez, J; Vida, M | 1 |
| Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS | 1 |
| Brown, KK; Carrick, KM; Chen, L; Clifton, LG; McNulty, JA; Pahel, GL; Stimpson, SA; Strum, JC; Winegar, DA; Yang, B | 1 |
| Adrogue, JV; Brown, KK; Burgmaier, M; Golfman, LS; Guthrie, PH; Sharma, S; Taegtmeyer, H; Van Arsdall, M; Wilson, CR; Young, ME | 1 |
| Carrick, KM; Clifton, LG; Lin, P; McNulty, JA; Pahel, GL; Stimpson, SA; Strum, JC; Winegar, DA; Yang, B | 1 |
| Cao, YL; Li, S; Liu, HY; Wang, LL; Xu, C; Zhou, XB | 1 |
| Brown, KK; Carrick, K; Chen, L; Clifton, LG; Geske, R; Han, B; McNulty, JA; Pahel, G; Qian, Y; Stimpson, SA; Strum, J; Triantafillou, JA; Yang, B | 1 |
| Cao, YL; Li, S; Liu, HY; Ruan, CM; Wang, LL; Xu, C; Zhou, XB | 1 |
| Braileanu, GT; Ding, SY; Hansen, BC; Ito, K; Tigno, XT | 1 |
| Moseley, RH | 1 |
| Berthault, MF; Dubar, M; Ferré, P; Ktorza, A; Morin, J; Pénicaud, L | 2 |
| Elhanany, E; Hemi, R; Kanety, H; Karasik, A; LeRoith, D; Paz, K; Zick, Y | 1 |
| Ikemoto, T; Ishikawa, Y; Saito, MN; Takeno, H; Tani, T; Watanabe, K | 1 |
| Kourilsky, O | 1 |
| Argengiano, L; de Luca, N; Guerrera, L; Iovino, GL; Izzo, R; Trimarco, B | 1 |
| Reid, JL | 1 |
| Brown, KK; Glass, CK; Li, AC; Palinski, W; Silvestre, MJ; Willson, TM | 1 |
| Schachter, M | 1 |
6 review(s) available for oxazoles and Insulin Sensitivity
| Article | Year |
|---|---|
Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes | 2010 |
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration | 2012 |
Clinical benefits of rilmenidine.
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Insulin Resistance; Middle Aged; Multicenter Studies as Topic; Oxazoles; Rilmenidine | 2000 |
The contribution of I1-selective agents in the management of syndrome X.
Topics: Antihypertensive Agents; Humans; Imidazoline Receptors; Insulin Resistance; Microvascular Angina; Oxazoles; Receptors, Drug; Rilmenidine | 2000 |
Rilmenidine: a clinical overview.
Topics: Albuminuria; Animals; Antihypertensive Agents; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance; Oxazoles; Rilmenidine; Treatment Outcome | 2000 |
Metabolic effects of moxonidine and other centrally acting antihypertensives.
Topics: Animals; Antihypertensive Agents; Diabetes Complications; Humans; Hypertension; Imidazoles; Insulin Resistance; Metabolism; Oxazoles; Rilmenidine; Sympathetic Nervous System; Sympatholytics; Syndrome | 1999 |
5 trial(s) available for oxazoles and Insulin Sensitivity
| Article | Year |
|---|---|
Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Thiophenes | 2018 |
The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
Topics: Adiponectin; AMP-Activated Protein Kinases; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycine; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Oxazoles; Oxidation-Reduction; PPAR alpha; PPAR gamma; Signal Transduction; Triglycerides | 2015 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Thiophenes | 2015 |
Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipid Metabolism; Metabolic Syndrome; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes; Treatment Outcome | 2016 |
Metabolic effects of muraglitazar in type 2 diabetic subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Intra-Abdominal Fat; Male; Middle Aged; Oxazoles; Peroxisome Proliferator-Activated Receptors | 2011 |
21 other study(ies) available for oxazoles and Insulin Sensitivity
| Article | Year |
|---|---|
Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
Topics: Acetyl-CoA Carboxylase; Acyl-CoA Dehydrogenase; Animals; Cells, Cultured; Disease Models, Animal; Fatty Acids; Gene Expression Regulation, Enzymologic; Hepatocytes; Histones; Insulin Resistance; Linoleic Acids, Conjugated; Lipogenesis; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Oxazoles; Oxidation-Reduction; PPAR alpha; Signal Transduction; Transcriptional Activation; Tyrosine | 2021 |
C333H ameliorated insulin resistance through selectively modulating peroxisome proliferator-activated receptor γ in brown adipose tissue of db/db mice.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Blood Glucose; Cell Line, Tumor; Diabetes Mellitus; Furans; Gene Expression Regulation; Humans; Insulin; Insulin Resistance; Leptin; Male; Mice; Obesity; Organ Size; Oxazoles; PPAR gamma; Rats; Rats, Wistar; Sodium Glutamate | 2013 |
Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice.
Topics: 3T3-L1 Cells; Acetates; Adipocytes; Albuminuria; Animals; Blotting, Western; Cells, Cultured; Cytokines; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression; Glucose; Inflammation Mediators; Insulin Resistance; Kidney; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Oxazoles; Podocytes; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Toll-Like Receptor 4 | 2013 |
Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Topics: Adipocytes; Adiponectin; Cell Line; Cell Movement; Cell Survival; Chemokine CCL2; Chemokine CXCL10; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Lipid Metabolism; Oxazoles; p38 Mitogen-Activated Protein Kinases; PPAR alpha; PPAR gamma; Thiophenes; Tumor Necrosis Factor-alpha | 2016 |
A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
Topics: Adipocytes; Animals; Cells, Cultured; Cyclooxygenase 2; Cytokines; Fatty Acids; Gene Expression Regulation; Glucose; Insulin Resistance; Lipid Metabolism; Macrophages; Matrix Metalloproteinase 9; Mice; Mice, Obese; Oxazoles; Oxidation-Reduction; Pipecolic Acids; PPAR alpha; PPAR delta; Stereoisomerism; Transcription, Genetic | 2010 |
Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Topics: Administration, Oral; Animals; Apolipoprotein A-I; Apolipoprotein A-II; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Eating; Glycated Hemoglobin; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Macaca mulatta; Male; Metabolic Syndrome; Obesity; Oxazoles; PPAR alpha; PPAR gamma; Prediabetic State; Thiophenes; Time Factors; Triglycerides; Weight Loss | 2011 |
A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
Topics: Analysis of Variance; Animals; Body Weight; Carbohydrate Metabolism; Cell Line; Computer Simulation; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Lipid Metabolism; Liver; Mice; Myocardial Reperfusion Injury; Oxazoles; PPAR alpha; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidines; Transfection | 2011 |
Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Amides; Animals; Blood Glucose; Cholesterol; Feeding Behavior; Gene Expression Profiling; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hydrogen Bonding; Insulin; Insulin Resistance; Ligands; Liver; Male; Models, Molecular; Oleic Acids; Oxazoles; PPAR alpha; Protein Binding; Rats; Solutions; Sulfonamides; Taste; Thermogenesis; Tyrosine; Weight Gain | 2012 |
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.
Topics: Adiponectin; Animals; Biomarkers; Carrier Proteins; Diabetes Mellitus; Fatty Acid-Binding Proteins; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Obesity; Oxazoles; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Thiazolidinediones; Tyrosine | 2004 |
Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.
Topics: Adaptation, Physiological; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Metabolism; Gene Expression Regulation; Glucose; In Vitro Techniques; Insulin Resistance; Male; Myocardial Contraction; Myocardium; Oxazoles; PPAR gamma; Rats; Rats, Inbred Strains; Rats, Zucker; Signal Transduction; Transcriptional Activation; Triglycerides; Tyrosine | 2005 |
PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Diabetes Mellitus, Experimental; Diet; Dose-Response Relationship, Drug; Insulin; Insulin Resistance; Male; Mice; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Tyrosine; Vascular Endothelial Growth Factor A | 2005 |
C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Blood Glucose; Cell Differentiation; Cell Line; Cholesterol; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Furans; Glucose Transporter Type 4; Hepatocytes; Humans; Insulin Resistance; Lipid Metabolism; Lipoprotein Lipase; Male; Mice; Oxazoles; PPAR alpha; PPAR gamma; RNA, Messenger; Triglycerides | 2006 |
Changes of skeletal muscle adiponectin content in diet-induced insulin resistant rats.
Topics: Adiponectin; Animals; Dietary Fats; Dietary Sucrose; Dose-Response Relationship, Drug; Insulin Resistance; Male; Muscle, Skeletal; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Tyrosine | 2006 |
A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism.
Topics: Adipocytes; Adipogenesis; Animals; Cell Differentiation; Diabetes Complications; Humans; Insulin Resistance; Lipid Metabolism; Male; Mice; Models, Animal; Oxazoles; PPAR alpha; PPAR gamma; Tyrosine; Up-Regulation | 2006 |
A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Topics: Animals; Apolipoproteins; Blood Glucose; Body Weight; Butyrates; Cholesterol, HDL; Dyslipidemias; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver Function Tests; Macaca mulatta; Male; Oxazoles; PPAR alpha; PPAR gamma; Prediabetic State; Treatment Outcome | 2007 |
Therapy for nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Cholagogues and Choleretics; Disease Models, Animal; Fatty Liver; Glycine; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Mice; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rats; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2008 |
[Effects of rilmenidine on rats made insulin resistant and hypertensive by a high fructose diet].
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Dietary Carbohydrates; Disease Models, Animal; Fructose; Hypertension; Insulin; Insulin Resistance; Oxazoles; Rats; Rats, Wistar; Rilmenidine | 1996 |
A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation
Topics: Animals; Binding Sites; Enzyme Inhibitors; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Marine Toxins; Okadaic Acid; Oxazoles; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Rats; Receptor, Insulin; Sphingomyelin Phosphodiesterase; Tumor Necrosis Factor-alpha; Tyrosine | 1997 |
Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Fructose; Hypertension; Insulin Resistance; Kinetics; Lipids; Male; Oxazoles; Rats; Rats, Wistar; Reference Values; Rilmenidine | 1998 |
Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals.
Topics: Administration, Oral; Animals; Deoxyglucose; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred Strains; Oxazoles; Phenylalanine; Rats; Rats, Inbred Strains; Rats, Wistar | 1998 |
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Arteriosclerosis; Base Sequence; CD36 Antigens; DNA Primers; Female; Gene Expression; Humans; Insulin Resistance; Ligands; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazoles; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tyrosine | 2000 |